13-disease-research-notes-research

Description

13 — Disease Research Notes (Research) — SKU 2040

Inventor: Christopher Gabriel Brown, sole proprietor, Lawrenceville, GA, USA. System: Alchemy Data V2 — a correlation-based elemental analysis database of 36,456 compounds. Patent posture: method-claim patent filing in preparation; coverage scope to be confirmed prior to engagement. Any patent that issues from filings covering this invention is retained by the inventor with all rights to prosecute, maintain, license to others, and enforce. The underlying inventor corpus is copyrighted © 2017–2026 Christopher Gabriel Brown and is referenced in the deliverable for provenance only. This listing conveys the on-disc deliverable as a research and documentation package; it is not a grant of the underlying method-claim patent strategy and it is not a medical device, drug, or therapy.

Regulatory posture: this is computational research , not medical advice, not an FDA-approved treatment, not a clinical validation, and not a pharmaceutical preparation. The formulations described inside the package are theoretical and have not been synthesised for medical use, tested in cell cultures or animals, reviewed by any regulatory agency, or validated through clinical trials of any phase. Every research document inside this package carries the same disclaimer at its head. Buyers of this package are buying a computational research corpus for laboratory reference, method-comparison, curriculum construction, IP diligence, and downstream in-vitro follow-up planning — not treatments.

Overview

This package is a single, self-contained computational research corpus covering 300 diseases and medical conditions . Each disease has its own dedicated research document, generated by running the Alchemy Data V2 elemental correlation engine against a curated 36,456-compound library and mapping the matches onto the biochemistry of the target condition. Each document is structured identically across all 300 diseases so a reader can pivot from one condition to another without re-learning the layout. Every document contains a theoretical serum formulation, a primary transformation pathway plus three alternative pathways, a multi-degree probability matrix, quality-control checkpoints, and a full elemental-composition breakdown. Roughly one disease in five (~19 %) carries an additional pharmaceutical cross-reference layer with FDA-approved drug data where public data allowed. The total documentation footprint is approximately 450,000 lines of research text across the 300 disease files and ~28 supporting documents, plus 58 Python analysis scripts, plus a Chemical Cooker interoperability bridge that emits 45 physical G-code recipes for a separately-acquired robotic cooker platform.

The intended reader is a pharmaceutical or biotech R&D team, a contract research organisation, an academic medical centre, an IP holding company, or an independent inventor who wants a systematic elemental-correlation starting point across the non-opioid disease space. The intended use is as a research substrate — a starting map that shortens the “where do I even begin?” phase of compound-candidate screening — not as a treatment protocol. The scoring inside the package is mathematical overlap, not clinical efficacy. That distinction is repeated everywhere it matters inside the package and is the single most important thing to understand before opening the disc.

Package generated 2026-05-02 (manifest); 2026-01-12 (final expansion & verification); 2026-03-12 (improvements)

Patent status Method-claim patent filing in preparation; coverage scope to be confirmed prior to engagement

Category positioning Medical & Pharma · Patent-Filed IP · Research Documentation

Delivery mechanism Blu-ray disc, AES-256 encrypted archive, passphrase sent separately by email

What the corpus is (and what it is not)

The corpus is a systematic, computational search for elemental patterns that overlap with disease mechanisms . It works by (1) categorising each of the 300 target conditions into one of 16 medical categories; (2) mapping each category to a profile of chemically-relevant elements — e.g. cardiac conditions to H, C, N, O, Mg, K, Ca; endocrine/thyroid conditions to H, C, N, O, I, Se; neurological conditions to H, C, N, O, Mg, Ca; blood conditions to H, C, N, O, Fe, Cu; (3) searching the Alchemy Data V2 database for compounds whose elemental composition matches those profiles; (4) generating transformation pathways, probability matrices, and theoretical serum recipes for the matches; and (5) cross-referencing against published pharmaceutical databases where such references are available. The output is a per-disease report that a downstream researcher can use as a first-pass literature-substitute for “what elemental candidates are worth looking at for condition X, and by what mechanism might they act.”

The corpus is not drug discovery, clinical validation, efficacy testing, medical advice, or a substitute for the standard scientific pipeline (synthesis → in vitro → in vivo → clinical trials → regulatory approval). “Discovery scores” reflect database coverage and mechanism overlap, not therapeutic probability. “Probability” values are mathematical calculations from the Alchemy system, not clinical success rates. “Serum recipes” are theoretical formulations, not validated pharmaceutical preparations. Sharing elements between a compound and a disease mechanism does not mean the compound treats the disease. Only ~19 % of the 300 conditions carry any verified pharmaceutical cross-reference in the package; the remaining ~81 % rest on Alchemy Data V2 elemental correlation alone and require independent scientific validation before any therapeutic reading is drawn from them.

Chemical Cooker recipes emitted 45 compounds across 10 medical categories → 90 files (JSON + G-code) + 1 manifest

Total files in package (per manifest) 398

Documentation: 322 files, Source code: 60 files, Data: 8 files, Web: 3 files, Archives: 2 files, Images: 1 file, Other: 2 files

Every one of the 300 core conditions in the numbered list is a condition that is typically managed without opioids as primary treatment . That framing is deliberate: the corpus was scoped away from pain-management pharmacology to keep the elemental-correlation work focused on mechanism analysis rather than analgesic substitution.

What is inside a single disease document

Each of the 300 NNN-Disease-Name-RESEARCH.md files opens with the standard disclaimer paragraph and then follows a fixed nine-section layout so a reader can jump straight to the section they need. A typical file is 1,200 – 1,636 lines long. The sections are:

Section What it contains

1. Disease overview Comprehensive description of the condition, category, and mechanism context.

2. Disease-specific alchemy compound formulation Primary compound identification (name, molecular formula, molecular weight in g/mol), elemental composition, target concentration in molarity, final serum volume, disease-specific element rationale.

3. Serum preparation recipe (theoretical) Recipe overview (serum name, primary compound, molecular weight, target concentration, final volume, preparation time, shelf life, storage conditions), required equipment list (analytical balance to ±0.0001 g, Class A volumetric flasks, pH meter, magnetic stirrer with hot plate, temperature-controlled water bath, fume hood, refrigerator, 0.22 µm sterile filtration, autoclave), safety equipment list, required materials with pharmaceutical-grade purities (≥99.9 %), solvent specification (WFI, USP grade, pyrogen-free), stabilisers (phosphate buffer pH 7.4, benzyl alcohol preservative, ascorbic acid antioxidant), quality-control reagents.

4. Step-by-step preparation procedure Phase 1 — laboratory preparation and setup (~30–45 min): work-surface decontamination with 70 % isopropanol, equipment verification, fume-hood airflow check (≥100 fpm), sterile work-area preparation, temperature/humidity verification (20–25 °C, 40–60 % RH), material-purity verification, weight/molecular-weight verification, balance and pH-meter calibration. Phase 2 — compound synthesis (~1–3 h): stoichiometric calculation, element combination, controlled synthesis reaction (temperature commonly 200–500 °C per alchemy transformation data), reaction monitoring (mass spectrometry, IR spectroscopy, elemental analysis), reaction completion verification (≥95 % conversion). Phase 3 — purification and formulation (~1–2 h): distillation/crystallisation to ≥99.0 % purity, 0.22 µm sterile filtration, dilution to target molarity, buffer & stabiliser addition. Phase 4 — quality control & release testing: pH verification, sterility check, endotoxin check, concentration verification, particulate inspection.

5. Transformation pathways A primary pathway plus three alternative pathways (A, B, C) per disease. Each pathway carries multi-step synthesis sequences, intermediate compound identification, reaction conditions (temperature, pressure, catalyst, reaction time), pathway efficiency and yield estimates, and optimisation strategies. Quality-control checkpoints are attached at each step.

6. Probability analysis matrix Multi-degree probability calculations at the 1st, 12th, 24th, 192nd, and 240th degree, mechanism-overlap scores, compound-match confidence levels, yield predictions, and synthesis-strategy recommendations. These are mathematical calculations from the Alchemy system — not clinical success rates.

7. Biological mechanism mapping Disease-specific pathway mapping: how the identified elemental profile is postulated to intersect with the disease's known biochemistry (e.g. Zn for insulin function in diabetes, Fe as tyrosine-hydroxylase cofactor for dopamine synthesis in Parkinson's, Zn/Cu/S/P clusters for amyloid clearance and tau regulation in Alzheimer's). Includes valence-electron analysis and living pH-balance protocols.

8. Pharmaceutical cross-reference (where available) For approximately 57 of the 300 conditions: FDA-approved drug data covering mechanism of action, indicated dosages, pharmacokinetic parameters, drug–drug interactions, and contraindications, presented alongside the alchemy-derived compound suggestions.

9. Treatment categorisation Classification of the derived approach as Established / Novel / Hybrid; regenerative vs inhibitory vs modulatory mechanism type; compound classification (organic, inorganic, complex, biologic); postulated administration route (oral, IV, topical, etc.).

Compound engine: Alchemy Data V2

Alchemy Data V2 is Christopher Gabriel Brown's correlation-based elemental analysis database. It holds 36,456 elemental combinations, each carrying its transformation pathways, synthesis methods, and probability scores. The database is not a drug library; it is an elemental-combination catalogue with cross-linked transformation data . The engine drives every match in this package.

Component What it does inside the corpus

Alchemy compound loader Loads 36,456 elemental combinations with their metadata (formula, molecular weight, transformation index, synthesis-catalogue reference, probability score).

Synthesis catalogue integration Retrieves temperature, pressure, catalyst, reaction time, and yield data for each compound's known synthesis routes, and templates them into the per-disease preparation procedure.

Transformation database Provides multi-step transformation sequences, intermediate compounds, and reaction conditions per compound. Feeds both the primary and the three alternative pathways per disease.

Probability matrix system Emits multi-degree (1st, 12th, 24th, 192nd, 240th) probability calculations and yield predictions per compound-disease pairing.

Category-to-element mapper Runs the 16-category → element-profile lookup table so disease-specific elements are selected (e.g. Zn for diabetes, Fe for Parkinson's, Zn+Cu for Alzheimer's) instead of generic H(CNO) matches.

Pharmaceutical cross-search Where a match exists in the public pharmaceutical databases, pulls FDA-approved drug data (mechanism, dosage, pharmacokinetics, interactions, contraindications) and attaches it to the disease document.

Comprehensive improvement system Central orchestrator that binds loader, catalogue, transformation, and matrix subsystems into a single generation pipeline ( comprehensive_improvement_system.py ).

Viral / infection H, C, N, O, S, Zn Zn for immune-function and viral-replication interference; S for cysteine-linked antiviral mechanisms.

Cardiovascular H, C, N, O, Mg, K Mg & K for cardiac conduction, electrolyte balance, vasodilation.

Neurological H, C, N, O, Mg, Ca Mg & Ca for neurotransmitter release, synaptic function, NMDA modulation.

Endocrine / thyroid H, C, N, O, I, Se I is core to T3/T4 synthesis; Se is essential for deiodinase enzymes.

Respiratory H, C, N, O, S, Mg S for mucin biology and glutathione defence; Mg for bronchodilation.

Kidney H, C, N, O, K, P K & P for electrolyte and acid-base homeostasis and phosphate handling.

Liver H, C, N, O, S, Zn S for glutathione/methionine cycles; Zn for hepatic enzyme function.

Bone / joint H, C, N, O, Ca, P Ca & P for hydroxyapatite matrix and bone remodelling.

Blood H, C, N, O, Fe, Cu Fe for haem biosynthesis; Cu for ceruloplasmin and iron mobilisation.

Cancer H, C, N, O, S, Zn, Se Se & Zn for antioxidant and DNA-repair enzymology; S for glutathione.

Skin H, C, N, O, S, Zn S for keratin cross-links; Zn for wound healing and epithelial turnover.

Mental health H, C, N, O, Mg, Zn Mg for GABAergic modulation; Zn for BDNF and mood-regulation pathways.

Gastrointestinal H, C, N, O, S, Zn S for tight-junction proteins; Zn for gut-barrier integrity.

Worked disease examples (from the package's own comparison analysis)

Disease (ID) Compound formula chosen by the engine Element-specific rationale Candidate mechanisms documented

Diabetes Mellitus Type 1 (126) and Type 2 (127) H(CNOZn) Zinc is critical for insulin function; matches proven insulin-mimetic research on zinc-amino-acid complexes; PubMed citations PMID: 11383627, PMID: 18989849. Beta-cell regeneration, insulin regeneration, glucose-metabolism restoration, cell regeneration, growth-factor support (5 mechanisms).

Alzheimer's Disease (157) H(CNOZn) with C-H-O-N-S, C-H-O-N-P, C-H-O-N-Cu alternatives Zn prevents amyloid aggregation; Cu supports amyloid clearance; S regulates tau protein; P supports the cholinergic system. Amyloid reduction, tau regulation, synaptic function restoration (zinc-dependent), BDNF enhancement, neuroinflammation reduction, neuronal regeneration, cholinergic support (7 mechanisms).

Parkinson's Disease (156) H(CNOFe) with C-H-O-N-S, C-H-O-N-P, C-H-O-N-Zn alternatives Iron is an essential cofactor for tyrosine hydroxylase — the rate-limiting enzyme in dopamine synthesis; Zn supports the dopamine transporter; S supports the glutathione antioxidant system; P supports mitochondrial ATP synthesis. Dopamine synthesis support, dopamine neuron regeneration, alpha-synuclein aggregation prevention, mitochondrial function restoration, glutathione system support (5 mechanisms).

Influenza Type A (001) — representative infectious sample HCl (primary), MW 36.46 g/mol, 0.5 M target, 1.0 L final volume, 3–6 h prep, 24–48 h shelf life at 2–8 °C, dark glass storage Category-1 infectious profile (H, C, N, O, S, Zn) applied to viral entry / replication interference. Full 1,636-line document with equipment list, reagent list, four-phase preparation procedure, transformation pathways A/B/C, and probability matrix.

The 300 diseases (full disease list)

Category 1 — Infectious Diseases (001–050): Influenza Type A; Influenza Type B; Influenza Type C; Common Cold (Rhinovirus); COVID-19 (SARS-CoV-2); HIV/AIDS; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E; Tuberculosis (Pulmonary); Tuberculosis (Extrapulmonary); Pneumonia (Bacterial); Pneumonia (Viral); Pneumonia (Fungal); Meningitis (Bacterial); Meningitis (Viral); Meningitis (Fungal); Encephalitis; Sepsis; Urinary Tract Infection; Strep Throat; Scarlet Fever; Diphtheria; Pertussis (Whooping Cough); Tetanus; Cholera; Typhoid Fever; Malaria; Dengue Fever; Yellow Fever; Zika Virus; West Nile Virus; Lyme Disease; Rocky Mountain Spotted Fever; Chlamydia; Gonorrhea; Syphilis; Herpes Simplex Virus Type 1; Herpes Simplex Virus Type 2; Varicella-Zoster (Chickenpox); Varicella-Zoster (Shingles); Epstein-Barr Virus (Mononucleosis); Cytomegalovirus; Human Papillomavirus (HPV); Rotavirus; Norovirus; Giardiasis; Amebiasis.

Category 2 — Cardiovascular Diseases (051–075): Hypertension (Primary); Hypertension (Secondary); Coronary Artery Disease; Myocardial Infarction; Angina Pectoris; Heart Failure (Systolic); Heart Failure (Diastolic); Atrial Fibrillation; Atrial Flutter; Supraventricular Tachycardia; Ventricular Tachycardia; Bradycardia; Heart Block (First Degree); Heart Block (Second Degree); Heart Block (Third Degree); Arrhythmia (Unspecified); Cardiomyopathy (Dilated); Cardiomyopathy (Hypertrophic); Cardiomyopathy (Restrictive); Pericarditis; Endocarditis; Myocarditis; Aortic Stenosis; Mitral Valve Prolapse; Peripheral Artery Disease.

Category 3 — Respiratory Diseases (076–100): Asthma (Mild); Asthma (Moderate); Asthma (Severe); COPD; Emphysema; Chronic Bronchitis; Bronchiectasis; Cystic Fibrosis; Pulmonary Fibrosis; Sarcoidosis; Pneumothorax; Pleural Effusion; Pulmonary Embolism; Pulmonary Hypertension; Sleep Apnea (Obstructive); Sleep Apnea (Central); Allergic Rhinitis; Sinusitis (Acute); Sinusitis (Chronic); Laryngitis; Pharyngitis; Tonsillitis; Bronchitis (Acute); Bronchitis (Chronic); Respiratory Syncytial Virus (RSV).

Category 4 — Gastrointestinal Diseases (101–125): GERD; Peptic Ulcer (Gastric); Peptic Ulcer (Duodenal); Crohn's Disease; Ulcerative Colitis; Irritable Bowel Syndrome (IBS); Celiac Disease; Diverticulitis; Diverticulosis; Gastritis; Gastroenteritis; Colitis; Chronic Constipation; Chronic Diarrhea; Hemorrhoids; Anal Fissure; Gallstones; Cholecystitis; Pancreatitis (Acute); Pancreatitis (Chronic); Autoimmune Hepatitis; Cirrhosis (Alcoholic); Cirrhosis (Non-alcoholic); NAFLD; NASH.

Category 5 — Endocrine Disorders (126–150): Diabetes Mellitus Type 1; Diabetes Mellitus Type 2; Prediabetes; Gestational Diabetes; Hypothyroidism; Hyperthyroidism; Hashimoto's Thyroiditis; Graves' Disease; Thyroid Nodules; Goiter; Addison's Disease; Cushing's Syndrome; Hyperaldosteronism; Pheochromocytoma; Acromegaly; Gigantism; Dwarfism; Growth Hormone Deficiency; Diabetes Insipidus; SIADH; Hyperparathyroidism; Hypoparathyroidism; Osteomalacia; Rickets; Metabolic Syndrome.

Category 6 — Neurological Disorders (151–175): Epilepsy (Generalized); Epilepsy (Focal); Multiple Sclerosis (Relapsing-Remitting); Multiple Sclerosis (Primary Progressive); Multiple Sclerosis (Secondary Progressive); Parkinson's Disease; Alzheimer's Disease; Dementia (Vascular); Dementia (Lewy Body); Dementia (Frontotemporal); Amyotrophic Lateral Sclerosis (ALS); Huntington's Disease; Tourette Syndrome; ADHD; Autism Spectrum Disorder; Cerebral Palsy; Bell's Palsy; Trigeminal Neuralgia; Migraine (With Aura); Migraine (Without Aura); Tension Headache; Cluster Headache; Restless Legs Syndrome; Narcolepsy; Chronic Insomnia.

Category 7 — Musculoskeletal Disorders (176–200): Osteoarthritis (Knee); Osteoarthritis (Hip); Osteoarthritis (Hand); Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Gout; Pseudogout; Osteoporosis; Osteopenia; Fibromyalgia; Myositis; Polymyalgia Rheumatica; Bursitis; Tendinitis; Carpal Tunnel Syndrome; Tennis Elbow; Golfer's Elbow; Rotator Cuff Injury; Scoliosis; Kyphosis; Lordosis; Osteomalacia; Rickets; Paget's Disease of Bone.

Category 8 — Dermatological Conditions (201–225): Psoriasis (Plaque); Psoriasis (Guttate); Psoriasis (Pustular); Atopic Dermatitis (Eczema); Contact Dermatitis; Seborrheic Dermatitis; Acne Vulgaris; Rosacea; Vitiligo; Alopecia Areata; Urticaria (Hives); Angioedema; Dyshidrotic Eczema; Nummular Eczema; Keratosis Pilaris; Seborrheic Keratosis; Actinic Keratosis; Basal Cell Carcinoma; Squamous Cell Carcinoma; Melanoma; Fungal Skin Infections; Bacterial Skin Infections; Viral Skin Infections; Warts; Molluscum Contagiosum.

Category 9 — Hematologic Disorders (226–250): Iron Deficiency Anemia; B12 Deficiency Anemia; Folate Deficiency Anemia; Hemolytic Anemia; Aplastic Anemia; Sickle Cell Disease; Thalassemia; Hemophilia A; Hemophilia B; Von Willebrand Disease; Thrombocytopenia; Thrombocytosis; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Multiple Myeloma; Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis; Coagulation Disorders; Bleeding Disorders; Blood Clotting Disorders.

Category 10 — Psychiatric Disorders (251–275): Major Depressive Disorder; Persistent Depressive Disorder (Dysthymia); Bipolar Disorder Type I; Bipolar Disorder Type II; Cyclothymic Disorder; Generalized Anxiety Disorder; Panic Disorder; Social Anxiety Disorder; OCD; PTSD; Schizophrenia; Schizoaffective Disorder; Delusional Disorder; Brief Psychotic Disorder; Borderline Personality Disorder; Antisocial Personality Disorder; Narcissistic Personality Disorder; Avoidant Personality Disorder; Dependent Personality Disorder; Anorexia; Bulimia; Binge Eating; ADD; ADHD; Autism Spectrum Disorder.

Category 11 — Renal Disorders (276–290): Chronic Kidney Disease Stage 1; Stage 2; Stage 3; Stage 4; Stage 5; Acute Kidney Injury; Nephrotic Syndrome; Nephritic Syndrome; Polycystic Kidney Disease; Glomerulonephritis; Pyelonephritis; Kidney Stones (Calcium); Kidney Stones (Uric Acid); Kidney Stones (Struvite); Renal Failure.

Category 12 — Hepatic Disorders (291–300): Hepatitis A; Hepatitis B (Chronic); Hepatitis C (Chronic); Autoimmune Hepatitis; Primary Biliary Cholangitis; Primary Sclerosing Cholangitis; Wilson's Disease; Hemochromatosis; Alpha-1 Antitrypsin Deficiency; Liver Cirrhosis.

Extended appendix — Autoimmune: Systemic Lupus Erythematosus; Sjögren's Syndrome; Scleroderma; Myasthenia Gravis; Guillain-Barré Syndrome; Vasculitis; Polymyositis; Dermatomyositis. Genetic: Down Syndrome; Turner Syndrome; Klinefelter Syndrome; Marfan Syndrome; Ehlers-Danlos Syndrome; Neurofibromatosis; Tuberous Sclerosis; Fragile X Syndrome. Oncological (non-opioid managed): Breast Cancer (Early Stage); Prostate Cancer (Early Stage); Thyroid Cancer; Non-Melanoma Skin Cancer; Leukemia (Various Types); Lymphoma (Various Types). Metabolic: Obesity; Metabolic Syndrome; Hyperlipidemia; Hypercholesterolemia; Hypertriglyceridemia; Gout; Porphyria.

Chemical Cooker interoperability bridge (bundled)

The package includes a compatibility bridge that converts the 45 highest-confidence novel compound formulations (across 10 medical categories) from Alchemy Data V2 into Chemical Cooker recipe JSON plus G-code. If a buyer separately owns a Chemical Cooker robotic platform, the bridge lets that hardware physically prepare the theoretical formulations under its own laboratory supervision. Purchasing this package does not convey any right to the Chemical Cooker hardware or platform; that product is separately acquired. The bridge is inspection-only if the buyer does not own the Cooker.

Each compound emits two files — research_ _ _ .json (Cooker recipe JSON) and research_ _ _ .gcode (Cooker G-code) — plus a top-level MANIFEST.json . The JSON schema conforms to 16-chemical-cooker/platform/lite_alchemy/schema.json and carries source, compound name, enhanced & base formulas, disease category, match score, probability, therapeutic potential (theoretical), a formulation block (elements, volumes in µL, vessels, heat in Celsius, heat time in seconds, stir flag), the disclaimer, the safety reference, the step sequence (move / dispense / heat / stir / wait), and cooker metadata. Default deck positions are defined for reservoir_1–4, well_1–2, and waste; these are override-able in the Cooker platform config. Modes are: representative (one recipe per category = 10), all (every compound = 45), and inspect (list categories, list a category's compounds, top-N by probability, G-code for one).

Python analysis tooling (bundled)

The package ships 58 Python analysis scripts (60 counting utility helpers) under _internal/scripts/ , plus a PowerShell orchestrator. The scripts are what generated the 300 disease documents in the first place; a buyer may re-run them, modify them, extend the disease-to-element mapping, or point them at a different underlying compound database.

Script Function

FINAL_EXPANSION_ALL.py End-to-end orchestrator for the full 300-disease generation run.

expand_all_diseases.py , direct_expansion.py , batch_expand_all.py , run_all_expansions.py Phase 1 expanders — replace generic H(CNO) placeholders with disease-specific compounds using the category-to-element map.

add_transformation_pathways.py Phase 2 — injects the primary + three alternative transformation pathways per disease.

add_probability_matrices.py Phase 3 — injects the multi-degree probability matrices per disease.

add_serum_recipes.py Injects the standardised serum-preparation-recipe section per disease.

add_valence_assembly.py , cleanup_duplicate_valence.py Valence-electron analysis and de-duplication.

add_living_ph_balance.py Living pH balance protocol injection.

add_disclaimers_to_research.py , add_specific_details.py Standardises the top-of-document disclaimer and disease-specific details.

match_top20_diseases.py Priority pass for the top 20 diseases (higher-detail match).

extract_synthesis_methods.py Pulls temperature/pressure/catalyst/reaction-time/yield rows from the synthesis catalogue into each recipe.

cross_search_drug_studies.py , enhance_with_drug_database.py , expand_pharmaceutical_data.py Pharmaceutical cross-reference layer — adds FDA-approved drug data where available (~19 % coverage).

discover_medical_compounds.py , deep_alchemy_analysis.py Novel-compound discovery and deep alchemy analysis passes.

comprehensive_alchemy_research_system.py , comprehensive_improvement_system.py End-to-end orchestrators wiring the loader, catalogue, transformation database, and probability matrices.

create_life_saving_research.py , enhance_solutions.py Solution-enhancement passes across the 300-disease set.

categorize_treatments.py Assigns each derived treatment to Established / Novel / Hybrid, plus mechanism type and administration route.

final_verification.py , check_progress.py , verify_improvements.py Verification pipeline: pattern-matching correctness, UTF-8 read/write on all 300 files, content-replacement structural integrity, disease-specific matching sanity.

GENERATE-ALL-RESEARCH.ps1 PowerShell orchestrator for the whole generation run on Windows.

_internal/scripts/alchemy_compounds.json The Alchemy Data V2 compound library used by the pipeline.

_internal/scripts/MEDICAL_COMPOUND_DISCOVERY_REPORT.json The 45-compound discovery report across 10 medical categories that feeds the Cooker bridge.

_internal/scripts/DEEP_ALCHEMY_ANALYSIS.json Deep alchemy analysis output (mechanism-overlap scores, multi-degree probabilities).

_internal/scripts/FOUR_DATABASE_EXAMS_REPORT.json Four-database cross-check report.

_internal/scripts/EXPANSION_PROGRESS.json Per-file expansion-run status log.

findings/top2000_semiconductor_compounds.json & .csv Top-2000 compound rankings by cost, cost-per-element, score, and outcome, with function tags. Companion doc: TOP2000_COMPOUNDS_SUMMARY.md .

DISEASE_RESEARCH_REFERENCE_CHART_11x17.svg Wall-format (11×17) SVG reference chart of the whole corpus — category structure, element mapping, and cross-links at a glance.

Drawings_DIABETES_300_DISEASES/FIG_1_CHEMICAL_STRUCTURES (PDF + SVG) Chemical structures reference figure supporting the diabetes discovery narrative that anchors the 300-disease work.

FIG_2_METHODOLOGY_FLOWCHART (PDF + SVG) End-to-end methodology flowchart — category mapping through recipe emission.

FIG_3_COORDINATION_MECHANISMS (PDF + SVG) Coordination-chemistry mechanism figures explaining how the chosen elemental profiles interact at the molecular level.

FIG_4_16_CATEGORY_MATRIX (PDF + SVG) 16-category × element-profile matrix in a single figure.

README.md Master overview of the corpus, categories, methodology summary, key features, disclaimers, and required next-steps.

SAFETY_DISCLAIMER.md Standalone safety disclaimer — not medical advice, not FDA-approved, not clinically validated; known safety concerns around metal toxicity, drug interactions, pH and administration errors, sterility, and endotoxins.

METHODOLOGY.md How the research was conducted, what the scores mean, what the methodology is and is not.

DISEASES-LIST.md Complete named-list of all 300 diseases with category numbering.

STATUS.md 100 % completion status with the expansion history, milestone log, verification checkpoints, and category-element mapping.

CHANGELOG.md Change log — 2026-01-12 compound updates, 300-file expansion, pharmaceutical data expansion to ~19 % coverage, scripts & tooling additions.

IMPROVEMENTS.md Honest status assessment: what is complete (computational scaffolding across all 300), what remains (independent pharmaceutical validation for ~81 %, no clinical trials, no peer review, no regulatory submissions), gaps and priorities, key metrics table.

COMPARISON_WITH_DEDICATED_DISCOVERIES.md Detailed comparison against dedicated single-disease discovery projects (10 — Diabetes, 11 — Alzheimer's, 12 — Parkinson's) with worked compound-selection, mechanism, and validation comparisons.

WORK_QUALITY_ASSESSMENT.md Commercial-quality assessment: what may confidently be charged for, what disclosures are required.

IP_NOTICE.md Open-research notice — author, terms of use, commercial-development note.

LICENSE Proprietary and confidential; © 2026 Christopher Gabriel Brown; no license granted absent express written permission; patent notice.

MANIFEST.json Machine-readable manifest — 398 files, 322 documentation / 60 source / 8 data / 3 web / 2 archives / 1 image / 2 other; top extensions; key artifacts.

CITATION.cff Citation file for academic reference.

PLAYBOOK.md Internal playbook — identity, folder inventory, README-at-a-glance, hook lines, reply patterns, status & gaps, quick links.

CONTACT_INFO.txt Author, address, email, store URL.

300-diseases-overview.html Web-format overview of the 300-disease scope.

START_HERE.html Human entry-point page.

WEB_DESCRIPTION.html Web-format long-form description of the corpus.

research/RESEARCH-INDEX.md Full index of all 300 disease documents, category-grouped.

research/ALCHEMY_COMPOUND_MATCHING_SUMMARY.md Summary of compound-matching outcomes across the 300-file set.

research/FINAL_ALCHEMY_MATCHING_REPORT.md Final matching report at project completion.

research/DRUG_STUDIES_CROSS_SEARCH_SUMMARY.md Summary of pharmaceutical-database cross-searches.

research/TREATMENT_CATEGORIZATION_REPORT.md Established / Novel / Hybrid categorisation across all 300 diseases.

findings/TOP2000_COMPOUNDS_SUMMARY.md Companion summary of the 2000-compound rankings (cost, score, function tags).

cooker_compat/COOKER_COMPATIBILITY.md Chemical Cooker interoperability write-up (bridge, coverage, modes, schema, deck positions, IP boundary).

_internal/RESEARCH-TEMPLATE.md Master template that every 300 disease document conforms to.

_internal/DIABETES_ALCHEMY_SECTION.md Reference alchemy section for the diabetes anchor case.

_internal/EXACT_DATA_EXTRACTION_SUMMARY.md Data-extraction provenance summary.

_internal/SCRIPTS_VERIFIED_WORKING.md , _internal/VERIFICATION_SUMMARY.md , _internal/PROGRESS_STATUS.txt Script-verification and progress logs.

13-disease-research-research.zip , _internal/files.zip Pre-packaged archives of the corpus and the internal materials.

Research substrate for R&D screening Use the 300 per-disease documents as a first-pass elemental-candidate map. Shortlist compounds by category profile before committing to wet-lab work.

Curriculum & training material Point graduate students and junior researchers at a single self-consistent 450,000-line corpus that spans 300 conditions in one uniform layout — a rare thing in medicinal chemistry teaching material.

IP diligence Use the corpus, comparison analysis, and improvement notes as a due-diligence artefact when evaluating separate acquisition of the licensor's dedicated single-disease discovery projects (Diabetes / Alzheimer's / Parkinson's).

Pipeline extension Modify the 58 Python scripts to point at your own compound database, add new categories, or extend the disease-to-element map. Every script is inspectable.

Chemical Cooker recipe drop-in If a Chemical Cooker is separately owned, load the 45 emitted recipes and G-code into the platform for physical formulation under your own laboratory supervision.

Category-level mechanism review Use the category-element map, coordination-mechanism figures, and 16-category matrix figure to review mechanism reasoning across a whole category at once.

Pre-clinical planning Use the transformation-pathway and probability-matrix data to plan the in-vitro follow-up experiments that would be required to move any specific compound out of pure correlation into real evidence.

What the buyer cannot do with this package

• Prepare or administer the theoretical formulations for medical use. Nothing inside the package has been synthesised for medical use, tested in cell cultures or animals, reviewed by any regulatory agency, or validated through clinical trials of any phase.
• Treat this as medical advice or as a treatment protocol. It is not either of those things.
• Rely on the “probability” and “discovery score” numbers as clinical efficacy predictions. They are mathematical overlap scores from the Alchemy engine, not clinical success rates.
• Assume the ~81 % of diseases without a pharmaceutical cross-reference carry any external validation. They do not; they rest on Alchemy Data V2 elemental correlation alone.
• Take ownership of the underlying inventor corpus (copyrighted © 2017–2026 Christopher Gabriel Brown, referenced in the deliverable for provenance only) or of the method-claim patent strategy (retained by the licensor).

Known safety concerns (from the in-package safety disclaimer)

• Many of the compounds referenced contain toxic elements at therapeutic doses (copper, iron, manganese, selenium). Metal toxicity can cause organ damage, neurological harm, or death.
• Drug interactions with existing medications have not been studied for any formulation in the corpus.
• pH, concentration, and administration-route errors on a theoretical formulation can be lethal.
• No quality control or purity validation has been performed on any of the theoretical preparations.
• Sterility and endotoxin testing have not been conducted.
• The formulations are theoretical outputs of a computational analysis and must not be prepared or administered outside a qualified pharmaceutical laboratory under proper regulatory oversight.

Required steps before any clinical application (as documented inside the package)

• Independent verification — third-party validation of compound data.
• Synthesis — laboratory synthesis of identified compounds.
• In vitro studies — cell-culture testing and mechanism validation.
• Animal studies — pre-clinical testing in appropriate animal models.
• Safety studies — comprehensive toxicology and safety assessment.
• Clinical trials (Phase I – III) — human safety and efficacy testing.
• Regulatory approval — FDA or equivalent regulatory body approval.

The 300 disease research documents, the 58 Python scripts, the data files, the figures, the reference chart, and all supporting documentation as delivered on this disc Buyer receives a copy for research and reference use as documented on the disc. Rights to the underlying inventor corpus and method claims are not conveyed.

Underlying inventor corpus (© 2017–2026 Christopher Gabriel Brown) Retained by the licensor. Referenced in the deliverable for provenance only. Not part of any grant.

Method-claim patent strategy (patent filing in preparation; coverage scope to be confirmed prior to engagement) Retained by the licensor with all rights to prosecute, maintain, license to others, and enforce.

Trademarks — “Cri-One,” “Disease Mechanism Research,” and related product designations Trademarks of the licensor. Descriptive attribution is permitted; adoption as the buyer's own product name is not.

Chemical Cooker hardware / platform Separately acquired product. Purchasing this package does not convey any right to the Chemical Cooker.

Dedicated single-disease discovery projects (Project 10 — Diabetes, Project 11 — Alzheimer's, Project 12 — Parkinson's) Separate products with separate acquisition paths. This package references them for comparison only.

• 300 individual disease research documents in research/ , named NNN-Disease-Name-RESEARCH.md , ~1,200–1,636 lines each, totalling ~450,000+ lines of documentation. Each file carries the standard nine-section layout: disease overview; disease-specific alchemy compound formulation; theoretical serum preparation recipe with equipment, materials, and reagent lists; step-by-step preparation procedure (four phases — setup, synthesis, purification, QC); transformation pathways (primary plus alternatives A, B, C); multi-degree probability analysis matrix; biological mechanism mapping with valence-electron and pH-balance analysis; pharmaceutical cross-reference (~19 % of diseases); and treatment categorisation (Established / Novel / Hybrid).
• 5 research-level index and summary documents in research/ : RESEARCH-INDEX.md , ALCHEMY_COMPOUND_MATCHING_SUMMARY.md , DRUG_STUDIES_CROSS_SEARCH_SUMMARY.md , FINAL_ALCHEMY_MATCHING_REPORT.md , TREATMENT_CATEGORIZATION_REPORT.md .
• 28 root-level documentation files : README.md , SAFETY_DISCLAIMER.md , METHODOLOGY.md , DISEASES-LIST.md , STATUS.md , CHANGELOG.md , IMPROVEMENTS.md , COMPARISON_WITH_DEDICATED_DISCOVERIES.md , WORK_QUALITY_ASSESSMENT.md , IP_NOTICE.md , LICENSE , MANIFEST.json , CITATION.cff , PLAYBOOK.md , CONTACT_INFO.txt , 300-diseases-overview.html , START_HERE.html , WEB_DESCRIPTION.html , and additional internal-verification and status files.
• 58 Python analysis scripts (60 counting utility helpers) under _internal/scripts/ , plus a PowerShell orchestrator ( GENERATE-ALL-RESEARCH.ps1 ) — the full pipeline that generated the corpus, re-runnable and modifiable.
• 8 data files : alchemy_compounds.json , MEDICAL_COMPOUND_DISCOVERY_REPORT.json , DEEP_ALCHEMY_ANALYSIS.json , FOUR_DATABASE_EXAMS_REPORT.json , EXPANSION_PROGRESS.json , findings/top2000_semiconductor_compounds.json and .csv , and findings/TOP2000_COMPOUNDS_SUMMARY.md .
• Reference figures : DISEASE_RESEARCH_REFERENCE_CHART_11x17.svg (large-format overview chart) plus Drawings_DIABETES_300_DISEASES/ containing FIG_1_CHEMICAL_STRUCTURES , FIG_2_METHODOLOGY_FLOWCHART , FIG_3_COORDINATION_MECHANISMS , and FIG_4_16_CATEGORY_MATRIX , each in PDF and SVG form.
• Chemical Cooker interoperability bridge in cooker_compat/ : bridge generator ( disease_compound_to_recipe.py ), compatibility write-up ( COOKER_COMPATIBILITY.md ), and the recipes/ output tree with 45 compound recipes across 10 medical categories (JSON + G-code pairs) plus a top-level MANIFEST.json .
• Web-format entry points : START_HERE.html , 300-diseases-overview.html , and WEB_DESCRIPTION.html .
• Sales-pitch materials under sales-pitches/ : three Proof-of-Function documents (HTML + PDF pairs), a product-card metadata file, a store-product-description HTML file, and a vault-delivery-instructions HTML file — inspection-only reference for the buyer's own presentation of the corpus.
• Pre-packaged archives : 13-disease-research-research.zip (the whole corpus zipped) and _internal/files.zip (internal materials zipped) — convenient for import into other tools.
• Manifest total : 398 files on disc — 322 documentation, 60 source code, 8 data, 3 web, 2 archives, 1 image, 2 other — consistent with the machine-readable MANIFEST.json at the root.
• Standard disclaimers, safety warnings, license, and citation file present at the root and repeated at the head of every disease document.

How this is delivered

This package ships on a single Blu-ray disc, posted to the delivery address on your order. The archive on the disc is AES-256 encrypted; the passphrase is sent separately, by email, once the disc is despatched — so the disc alone is of no use to anyone who intercepts it.

Discs are despatched by tracked, signed-for post. Allow 5 business days for mastering and verification before despatch.

File names inside the package may use older working titles.

© 2026 Christopher Gabriel Brown. All rights reserved.

Photo